This phase III trial compares memantine to placebo in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving…
- Investigator
- Brian Stover
- Ages
- 4 Years - 17 Years
- Sexes
- All